Hepatitis C

Top Story

Occult HBV does not affect HCC resection outcomes

July 24, 2017

The presence of hepatitis B core antibody, or HBcAb, did not affect the outcomes of hepatic resection in patients with either hepatitis C-related or non-B, non-C hepatocellular carcinoma, according to results of a recent study. However, the data showed a possible link between occult hepatitis B infection and hepatocarcinogenesis in patients with non-B, non-C HCC.

“Because measurement of HBcAb is not included in the regular screening protocol for HBV infection at many institutions, the actual prognostic influence of HBcAb-positivity in HCC patients remains unclear,” Shinji Itoh, MD, PhD, from the Graduate School of Medical Sciences, Fukuoka, Japan, and colleagues wrote. “Given the apparently high proportion of patients with a history of HBV, the clinical features of the HBcAb-positive subgroup of [non-B, non-C] HCC or HCV-related HCC patients need to be explored to allow for better clinical management of HCC.”

In the Journals

HCV rates climbing in younger HIV-positive MSM

July 20, 2017
Hepatitis C infection rates continue to increase in Northern Europe in recent years among younger men who have HIV and have sex with men, with those more recently…

FDA approves Vosevi for HCV

July 18, 2017
FDA announced the approval of Vosevi for the treatment of adults with chronic hepatitis C genotypes 1 through 6, according to an agency press release…
In the Journals

New EHR alert increases HCV screening among baby boomers

July 18, 2017
Implementation of an electronic health record-based prompt significantly increased hepatitis C screening rates among baby boomers in primary care. According to the…
More Headlines »
CME Video

Case Challenges in Pediatric Fatty Liver: What to Look For and When to Refer

This activity is supported by an educational grant from Synageva BioPharma Corp.

Non-alcoholic fatty liver disease (NAFLD) is characterized by excess fat deposition in the liver due to causes other…
More »
GI Bookshelf

Chapter 5: Quantification And Identification Of Probiotic Organisms In Humans

From Probiotics: A Clinical Guide
More »
Resource Centers
International Liver Congress

International Liver Congress

Video
Meeting News

VIDEO: C-CREST-1 trial shows fixed-dose combo effective at 8 weeks for HCV

November 14, 2016
More »
Advertisement
Advertisement